Why the study?
Long-term anti-ischemic drug therapy for chronic coronary syndromes requires adaptation to patient-specific clinical features and expected therapeutic benefits.
Answers are grounded in this paper and cite their sources.
May guide antianginal selection in type 2 diabetes; leaves open randomized confirmation of metabolic benefits.
The article highlights the stepwise strategy of long-term anti-ischemic drug therapy for patients with chronic coronary syndromes according to the 2019 European Society of Cardiology Recommendations, which should take into account certain features of the clinical course of the disease. The optimal approach should be adapted to the characteristics of each patient and the expected benefits from the prescribed therapy.
No takes yet. Share an insight, caveat, or question.
P. O. Lazarev (2022) conducted a review in Ischemic heart disease and comorbid type 2 diabetes mellitus. Antianginal therapy (vasodilatory beta-blockers, ranolazine, ivabradine, calcium channel blockers) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: